Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer

Sponsor
Hebei Medical University Fourth Hospital
Study ID
NCT03086785
Phase
PHASE2
Status
Unknown

Conditions

  • Breast Cancer Metastatic

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    apatinib 500mg qd po or combined capecitabine 1000mg/m2 bid d1-14 q3w

Study Details

The purpose of this study is to assess the efficacy and safety of patients who receive apatinib single or combined capecitabine for treatment of patients with metastatic her-2 negative breast cancer.

Key Dates

Start date
Nov 24, 2016
Status verified
Jan 2018
Primary completion
Nov 30, 2018
Completion
May 31, 2019

Study Design

Enrollment
120 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: apatinib
    apatinib 500mg qd po or combined Capecitabine 1000mg/m2 bid d1-d14 q3w

Primary Outcome Measure

Progression free survival [ Time Frame: evaluated in 24 months since the treatment began ]

Central Contacts

Related Studies